TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Coefficient of failure from fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in iron deficiency anaemia outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Amount excreted into the urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative positive blood culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative positive urine culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: interpremolar width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of the dental arch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate (CDAI < 150)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corticosteroid usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain-free daily living activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma amino acids levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean percent BMI loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of mucomembranous reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average repairing time for oral lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee extensor torque LSI at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MRI composite score at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: patient satisfaction with MACI surgery at 24 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discharge readiness by postoperative day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to the intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: reduction in psychological distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regulation of regional cerebral metabolic rates for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Good outcome in CBT group
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: new drug resistance
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma midazolam concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Midazolam central volume of distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Midazolam elimination clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude-scaled binocular accommodative facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture edge healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life related to chronic oral mucosal conditions
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of nets meeting WHO criteria for bio-efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of baseline insecticide dose after 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical integrity based on proportionate hole index after 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No rescue therapy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial hypertriglyceridemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: UPE measurement following UVA excitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: One-year freedom from atrial tachyarrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: One-year freedom from symptomatic atrial tachyarrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resection of malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrode impedances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CD4(+) T-cell increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological suppression (<50 copies/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rate for reconstructions and abutments
Endpoint domain: Mortality/survival
Primary endpoint: Discoloration of the soft tissue compared with the gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in risk of vertebral and nonvertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Increase in bone density of the lumbar spine and femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: FQR hazard ratio
Endpoint domain: Mortality/survival
Primary endpoint: 3mCDP hazard ratio
Endpoint domain: Mortality/survival
Primary endpoint: 6mCDP hazard ratio
Endpoint domain: Mortality/survival
Primary endpoint: Failure to control IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Preoperative IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Preoperative requirement for glaucoma drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Agreement with the attitude statement 'I am prepared to be a new mother'
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall agreement to attitudes against alcohol consumption during pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement of attitudes toward alcohol consumption
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Airway inflammation markers (neutrophil count, eosinophilic cationic protein, myeloperoxidase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF‐36 physical component summary
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF‐36 mental component summary
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SF 36 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Presence of fever during the first 24 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced urges for smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leaks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incontinence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time exposure to supplemental oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or higher toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of activations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with normal HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DM self efficacy scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in fungal growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical success (resolution of diarrhoea within 72 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of sialorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects requiring discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: decreased depressive symptoms at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decreased ICU costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: reduced ICU and hospital length of stay
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reexcision rates
Endpoint domain: Adverse events/effects
Primary endpoint: Functional recovery after revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: combined cardiac and neurologic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stroke rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cardiac complication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NPSC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of procalcitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral symptoms index at 7 years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Externalizing problems at 7 years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: School problems at 7 years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentrations greater than 0.7 ng/ml of buprenorphine and norbuprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minimal withdrawal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Social functioning improvements
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Physical function gains
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: General health aspects
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inhalation characteristics (PIF, ΔP, ACCEL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDA at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Procedure-related discomfort score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular punctures
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in vascular picture on microscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Advanced histologic signs in biopsy samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PTSD prevalence
Endpoint domain: Mortality/survival
Primary endpoint: Treatment failure during follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects reaching HbA1c ≤ 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean number of hypoglycaemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of major depressive disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypercirculatory instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DFT voltage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of Barrett's epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: depressive relapse/recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of major depression and dysthymia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of other anxiety disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of tic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of total outpatient treatment costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Onset of clinically significant bronchodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient satisfaction with medication onset
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Forearm muscle glucose clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of amputations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Days spent in the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total inpatient resources used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SBI (Salivary Bleeding Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: API (Approximal Plaque Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL‐1β (Interleukin-1 beta)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of caloric goals achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of GI complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Discrepancy between school and weekend out of bed times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Changes in CoP sway with eye closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PERF (Peak Expiratory Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEF25‐75% (Forced Expiratory Flow at 25-75% of FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: TXB2 inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of confirmed ROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Final ODI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Homeostatic model assessment of insulin resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: β-cell function (HOMA-β)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glycated hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: DRT (Driving Reaction Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in speech character
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in angina pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in hsCRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: post-operative catecholamine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: N400 response to subordinate homograph sentences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetics (Cmax and AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Small low-density lipoprotein particles (sLDL-P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non-high-density lipoprotein particles (non-HDL-P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of small high-density lipoprotein particles (sHDL-P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of bowel movements graded as 'normal'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean number of bowel movements per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease of negative stereotypes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Desired social distance
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Increase in perception of sociability
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Failure rate (IOP > 21 mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Improvement in visual acuity (logMAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five-hour gastric emptying (AUC(0-300 min))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: slip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma HDL cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: motor output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in airways resistance following bronchodilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Endothelial cell loss (ECL) from baseline to 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in SYNTAX score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SERS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum 5-HT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean BIS values throughout the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in bipolar depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Falls in FEV(1) after montelukast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Duration of epinephrine infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent sensory deficit
Endpoint domain: Adverse events/effects
Primary endpoint: Persistent motor deficit
Endpoint domain: Adverse events/effects
Primary endpoint: Persistent anterior thigh or groin pain
Endpoint domain: Adverse events/effects
Primary endpoint: average vasoconstrictor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protrusion and proclination of the mandibular incisors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevention of persistent weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Central apnea-hypopnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral blood flow velocity (CBFv)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial pressure of arterial carbon dioxide (PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth in height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean hemoglobin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Correct mapping of concepts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBDQ total scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient preferences for tofacitinib
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: death from cardiac causes
Endpoint domain: Mortality/survival
Primary endpoint: total catheter survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: simulated 40-km endurance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RIII reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VAS data
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: psychiatric healthcare utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Antibiotic-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper airway trauma
Endpoint domain: Adverse events/effects